IART INTEGRA LIFESCIENCES HOLDINGS CORP — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$19.01

Period return

+6.82 (+55.95%)

Volume

776.4K

2026-07-21O $18.85 H $19.29 L $18.63 C $19.01MA5 $19.16MA20 $18.39MA60 $16.03MA120 $13.19

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 07. 30.Highin 9 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 29.MediumHOLD2 months ago
Citigroup: Neutral
US analyst rating / recommendation change.
2026. 05. 07.LowSELL3 months ago
Citigroup: Sell
US analyst rating / recommendation change.
2026. 05. 06.LowHOLD3 months ago
Wells Fargo: Equal-Weight
US analyst rating / recommendation change.
2026. 04. 15.LowHOLD3 months ago
Truist Securities: Hold
US analyst rating / recommendation change.
2026. 04. 15.MediumHOLD3 months ago
Argus Research: Hold
US analyst rating / recommendation change.
2026. 03. 12.LowSELL4 months ago
Citigroup: Sell
US analyst rating / recommendation change.
2026. 02. 28.LowHOLD5 months ago
Wells Fargo: Equal-Weight
US analyst rating / recommendation change.
2025. 11. 04.LowHOLD9 months ago
Truist Securities: Hold
US analyst rating / recommendation change.
2025. 11. 01.LowSELL9 months ago
Citigroup: Sell
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $17.43 · 7 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 07. 30.	After market close (AMC)	$0.48	—	—	$417.62M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-0.33	—	—	$382.65M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-0.34	—	—	$1.17B	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-0.2	—	—	$787.05M	Reported

INTEGRA LIFESCIENCES HOLDINGS CORP

Price chart

Recent event timeline

Recent earnings

Research actions

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 29.	Citigroup	—	Upgrade	Sell → Neutral	—	Citigroup: Sell → Neutral
2026. 05. 07.	Citigroup	—	Maintain	Sell → Sell	—	Citigroup: Sell
2026. 05. 06.	Wells Fargo	—	Maintain	Equal-Weight → Equal-Weight	—	Wells Fargo: Equal-Weight
2026. 04. 15.	Truist Securities	—	Maintain	Hold → Hold	—	Truist Securities: Hold
2026. 04. 15.	Argus Research	—	Downgrade	Buy → Hold	—	Argus Research: Buy → Hold
2026. 03. 12.	Citigroup	—	Maintain	Sell → Sell	—	Citigroup: Sell